Gobind Singh
Stock Analyst at HC Wainwright & Co.
(n/a)
# 4,666
Out of 4,667 analysts
9
Total ratings
6.67%
Success rate
-56.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gobind Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Assumes: Buy | $35 | $20.31 | +72.33% | 1 | Sep 19, 2022 | |
| ELEV Elevation Oncology | Assumes: Buy | $7.5 | $0.58 | +1,190.66% | 1 | Sep 19, 2022 | |
| IMUX Immunic | Assumes: Buy | $26 | $1.07 | +2,329.91% | 2 | Sep 19, 2022 | |
| PRTA Prothena Corporation | Initiates: Market Outperform | $77 | $14.40 | +434.72% | 1 | Nov 19, 2021 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $60 → $70 | $40.65 | +72.20% | 4 | Nov 15, 2021 |
AnaptysBio
Sep 19, 2022
Assumes: Buy
Price Target: $35
Current: $20.31
Upside: +72.33%
Elevation Oncology
Sep 19, 2022
Assumes: Buy
Price Target: $7.5
Current: $0.58
Upside: +1,190.66%
Immunic
Sep 19, 2022
Assumes: Buy
Price Target: $26
Current: $1.07
Upside: +2,329.91%
Prothena Corporation
Nov 19, 2021
Initiates: Market Outperform
Price Target: $77
Current: $14.40
Upside: +434.72%
Protagonist Therapeutics
Nov 15, 2021
Maintains: Market Outperform
Price Target: $60 → $70
Current: $40.65
Upside: +72.20%